SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Oppenheimer Maintains Outperform on Recro Pharma, Lowers Price Target to $12

Oppenheimer maintains Recro Pharma (NASDAQ:REPH) with a Outperform and lowers the price target from $18 to $12.

Benzinga · 05/12/2020 12:20

Oppenheimer maintains Recro Pharma (NASDAQ:REPH) with a Outperform and lowers the price target from $18 to $12.